Bortezomib API
| Name of Product | Bortezomib API |
|---|---|
| CAS No | 179324‑69‑7 |
| Therapeutic use:- | Proteasome inhibitor; used in multiple myeloma & mantle cell lymphoma |
| Grade | IP |
| Form:- | API Powder |
| Status | Commercial |
Product Overview
Bortezomib API (CAS No. 179324-69-7) is the first-in-class proteasome inhibitor widely available in oncology.
Being a synthetic dipeptidyl boronic acid derivative, it reversibly inhibits the 26S proteasome.
Bortezomib API disrupts multiple signaling pathways, leading to cell cycle arrest and apoptosis in cancer cells.
This API is also seen as a treatment for blood cancers.
Therapeutic Applications
Multiple myeloma control for both newly diagnosed and relapsed/refractory multiple myeloma patients.
Helpful for patients with Mantle Cell Lymphoma who have had one treatment prior.
Research is ongoing for treating solid tumors and autoimmune disorders.
Specification Parameters
Packaging & Storage
Bortezomib API comes in different packaging options: customized vials, HDPE bottles, and sealed aluminum foil bags.
Storage has to be done under refrigerated conditions (2–8 °C).
Proper labeling is required to meet international standards.
Why Choose Us
We ensure our quality by following strict GMP and ISO guidelines. We also conduct thorough quality testing.
Reliable logistics ensure safe and timely delivery.
Custom solutions are available from us along with bulk quantities.
With years of experience, we adhere to all regulatory guidelines and supply products globally.